Background. Tropheryma whipplei is a bacterium that causes Whipple disease. However, T. whipplei can be carried in the gut of asymptomatic people, which may lead to difficulty in the interpretation of positive stool sample test results.
sic Whipple disease is essential, because the disease is potentially responsible for sequelae and can be fatal if left untreated. However, classic Whipple disease is still frequently misdiagnosed.
The development of a reliable culture method for in vitro growth of T. whipplei has made it possible to develop a noninvasive and accurate serological method to diagnose classic Whipple disease [1, [8] [9] [10] [11] [12] . However, several attempts to develop such a method have failed [1] . The crude antigens used in indirect immunofluorescence assay tests were initially found to be useful for detection of specific immunoglobulin (Ig) M, but specificity was lost within months [1] . Moreover, there was a paradoxical association of Whipple disease with a lower immunological response in patients, compared with asymptomatic carriers [13] . An antigenic shift in the bacteria, most likely linked to the glycosylation process, resulted in this loss of specificity [14] . An enzyme-linked immunosorbent assay that targeted part of the hsp65 gene was not accurate or reliable for distinguishing patients from control subjects [15] . A global immunoproteomic analysis of the T. whipplei proteome on the basis of 2-dimensional electrophoresis coupled to mass spectrometry and immunoblot analysis has identified 23 putative candidate antigenic proteins [16] . A set of 8 proteins could be used to successfully diagnose all of the patients studied, but the high specificity required for application in practical diagnosis was not demonstrated (62.5%). In addition, another study analyzed T. whipplei basic proteins to improve the detection of putative immunodominant bacterial antigens [17] . A sugar ABC transporter (TWT328) was the best marker found for development of serodiagnostic tests for classic Whipple disease, but the sensitivity of this marker was only 61%, and the specificity was 87%. Therefore, no attempts to propose an applicable serological diagnosis have been successful thus far.
On the basis of recent preliminary data [13, 14] , which suggested that antibody-mediated immune recognition is impaired in patients with classic Whipple disease when compared with T. whipplei asymptomatic carriers, we have developed and validated a novel method to distinguish these 2 populations.
PATIENTS, MATERIALS, AND METHODS

Study Subjects
Population recruitment. The study included 60 patients (58 French and 2 Italian patients) with classic Whipple disease (45 men and 15 women; age range, 27-78 years; mean age ‫ע‬ standard deviation [SD] , years) and 26 French T. whip-56 ‫ע‬ 13 plei asymptomatic carriers (24 men and 2 women; age range, 26-83 years; mean age ‫ע‬ SD, years). Among the 43 ‫ע‬ 13 asymptomatic carriers, 19 sewer workers and 7 patients with a diagnosis excluding Whipple disease were included. All patients and asymptomatic carriers previously received a diagnosis in our laboratory in Marseille, France, which is a reference center for the diagnosis of Whipple disease in our country [18] . The samples from patients and 7 asymptomatic carriers were sent to our laboratory for diagnostic purposes [18] , whereas the samples from the sewer workers were sent to our laboratory for epidemiological studies [6] .
Whipple disease and T. whipplei asymptomatic carriage definition. Our criteria to confirm a definite diagnosis of classic Whipple disease included the presence of positive results via periodic acid-Schiff-staining and/or specific immunohistochemistry of a small-bowel biopsy specimen [18, 19] . Our criteria to establish the status of 7 T. whipplei asymptomatic carriers included the lack of positive results via periodic acidSchiff-staining and/or specific immunohistochemistry of a small-bowel biopsy specimen and the presence of T. whipplei DNA in stool specimens. For the 19 sewer workers, the criteria for establishing the status of asymptomatic carriers were the lack of clinical manifestations and the presence of T. whipplei DNA in stool specimens [6] Follow-up phase. Serum samples from 32 patients with Whipple disease, which were sampled at least 6 months after the initiation of an adequate Whipple disease treatment (range, 6-72 months; mean duration ‫ע‬ SD, months), were 22 ‫ע‬ 16 also tested with Western blot to investigate the effect of antibiotic treatments on the total immunoglobulin response.
Western Blot Analyses
Western blot assays. Serological assays were performed using Western blot analysis. Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes. The Twist strain of T. whipplei was cultivated in axenic medium, as reported elsewhere [8] . The protein concentration of the samples was determined using a Bio-Rad reagent (Hercules). Native and deglyclosylated samples obtained from the total bacterial extract were prepared for SDS-PAGE. For deglycosylation, 100 mL of T. whipplei Twist proteins concentrated at 1 mg/mL were denatured with denaturant solution (octyl b-D-glucopyranoside 2% and 100 mmol/L 2-mercaptoethanol; Sigma-Aldrich Chimiee) for 5 min at 100ЊC. The suspension was then incubated for 30 h at 37ЊC with the following glycosidases: 5 mL of recombinant N-glycosidase F (PNGase F, 0.5 U/mL) from Flavobacterium meningosepticum (Roche Diagnostics), 5 mL of endoglycosidase H (PNGase H, 0.1 U/mL) from Streptomyces plicatus (Sigma-Aldrich Chimie), and 5 mL of exoglycosidase recombinant a(2r3,6,8,9) sialidase (0.1 U/mL) from Arthrobacter ureafaciens (Sigma-Aldrich Chimie). Native and deglyclosylated T. whipplei Twist cells were resuspended in Laemmli buffer (Sigma-Aldrich Chimie) containing 100 mmol/L dithiothreitol to obtain a final protein concentration of 0.5 mg/ mL and were heated for 5 min at 100ЊC. For each sample, 5 mg of protein were loaded into each well and were resolved using 7.5% SDS-PAGE. The proteins were then transferred onto nitrocellulose membranes (Trans-blot Transfer Medium, Pure Nitrocellulose Membrane, 0.45 mm; Bio-Rad) for a 2-h period with use of a semi-dry transfer unit (Hoeffer TE 77, GE Healthcare). The membranes were immersed in phosphate-buffered saline supplemented with 0.2% Tween 20 and 5% non-fat dry milk (blocking buffer) for 1 h at room temperature before incubation with primary sera (diluted 1:1000 in blocking buffer) for 1 h at room temperature. The membranes were then washed 3 times with phosphate-buffered saline and Tween 20, and immunoreactive spots were detected by incubating membranes for 1 h at room temperature with a peroxidase-conjugated goat anti-human antibody (Southern Biotech), which was diluted 1:1000 in the blocking buffer. The assay was performed to test a pool of IgG, IgM, and IgA heavy and light chains (total immunoglobulins), as well as IgG, IgM, and IgA separately (Southern Biotech). Detection was performed using chemiluminescence (ECL Western Blotting Analysis System) and an automated film processor (Hyperprocessor; GE Healthcare). Western blot interpretation. To quantify bands on Western blots, films were scanned with Image Scanner III (GE Healthcare). Image analysis was performed with GelEval 1.21b FrogDance software and ImageJ 1.39v software (Wayne Rasband National Institutes of Health). Parameters were measured in the regions of interest. For quantifying the signal decrease in the GpTw110 band after deglycosylation, we used the ratio of mean densities gly GpTw110/Dgly GpTw110, where gly GpTw110 is the density of the GpTw110 band minus background and Dgly GpTw110 is the density of the deglycosylated GpTw110 band minus background. Blot images were analyzed using ImageMaster 2D Platinum, version 6.0. (GE Healthcare), as described elsewhere [16] .
During our preliminary study, analysis of the signal intensity of GpTw110 after deglycosylation demonstrated a large, significant decrease in sera from patients but not from carriers [14] . These data were then used to establish a diagnostic test. Therefore, in this study, T. whipplei asymptomatic carriage was defined as the presence of a signal intensity of GpTw110 that was equal before and after deglycosylation. Classic Whipple disease detection was defined to be when the decrease in signal intensity of GpTw110 after deglycosylation was у40% or as when a lack of antibodies response was observed against both native and deglyclosylated T. whipplei, as reported elsewhere [14] .
Statistical Analysis
The statistical analysis was performed by Fisher's exact test with use of EpiInfo6 (http://www.cdc.gov/epiinfo/Epi6/EI6dnjp.htm). A differential expression was considered to be statistically significant when . The positive predictive value was defined P ! .05 as the proportion of true-positive results among true-positive and false-positive results. The negative predictive value was defined as the proportion of true-negative results among truenegative and false-negative results.
RESULTS
Screening phase. The serum samples of T. whipplei carriers displayed a significantly better immune response than did those of patients with classic Whipple disease. Immunoglobulins from the serum samples of patients with Whipple disease exhibited either a lack of immune response or a decrease in reaction to T. whipplei GpTw110 after deglycosylation (table 1) . When screening for total immunoglobulin, 56 (93%) of 60 patients with classic Whipple disease presented a Western blot profile consistent with infection, whereas only 5 (19%) of 26 carriers presented a profile consistent with infection ( ) P ! .001 ( figure 1) .
Among the 56 patients with Whipple disease, 23 lacked an antibody response, and 33 presented a response with decreased signal intensity of GpTw110 after deglycosylation. The results obtained with IgG were nearly identical to those obtained with total immunoglobulin. Only 4 patients with Whipple disease presented a response with IgM, and 1 patient presented a response with IgA. The decrease in signal intensity was observed not only for total immunoglobulin but also for other immunoglobulins. None of the 26 carriers presented an IgM or IgA response. Of the 5 carriers who presented a profile consistent with infection, 2 lacked a response, and 3 had a decreased response in signal intensity of GpTw110 after deglycosylation.
When data from this screening is analyzed considering a negative immune response, the positive predictive value for the diagnosis of classic Whipple disease is 92% for both total immunoglobulin and IgG, 68% for IgM, and 69% for IgA. If a positive immune response is considered at the signal intensity after deglycosylation, the negative predictive value is 39% for both total immunoglobulin and IgG and 0% for both IgM and IgA. When the decrease in signal intensity of the immune response after deglycolysation is considered, the positive predictive value for the diagnosis of classic Whipple disease is 92% for total immunoglobulin and IgG and 100% for IgM and IgA. If we consider a negative immune response or a decrease in signal intensity of the immune response after deglycosylation, the positive predictive value is 92% for total immunoglobulin and IgG and 70% for IgM and IgA.
Confirmatory phase. When screening for the total immunoglobulin present in the second set of serum samples, 34 Among the 4 patients with classic Whipple disease who exhibited a Western blot profile consistent with carriage during the first screening, an additional serum sample was available for only 1 patient, which confirmed the results that were obtained with the first serum sample. This patient was a 77-yearold man with arthralgias and diarrhea who received a diagnosis of Whipple disease in 2001; this diagnosis was based on positive periodic acid-Schiff-staining and specific immunochemistry on duodenal and synovial biopsies as well as positive immunochemistry on blood monocytes [19, 20] . The patient was lost to follow-up.
Among the 2 sewer workers with a Western blot profile consistent with infection, an additional serum sample was available for 1 worker. The same conclusion was obtained with both samples via Western blot assay. However, no antibody response was observed with the first serum sample, whereas a slight response was observed from the second serum sample, with a difference in the signal intensity of GpTw110 after deglycosylation. Two sewer workers who were considered to be asymptomatic carriers during the first screening presented a profile consistent with infection during the second screening, with a difference in the signal intensity of GpTw110 after deglycosylation. The blind test, which included 10 patients with Whipple disease and 10 asymptomatic carriers, corroborated the data obtained previously.
Follow-up phase. Among the 32 patients with Whipple disease who had a serum sample available after the beginning of antibiotic therapy, 11 presented a lack of response, and 21 exhibited a decrease in signal intensity after deglycosylation in the first screening. Among the 11 patients with a previous lack of response during the antibiotic therapy, 10 still presented a lack of total immunoglobulin response, and 1 patient displayed a decrease in signal intensity after deglycosylation. Among the 21 patients with a previous decrease of signal intensity after deglycosylation during antibiotic therapy, 19 still presented a decrease in signal intensity after deglycosylation, and 2 patients lacked a response. Thus, the antibiotic therapy had no effect on Western blot profiles.
Finally, the follow-up analysis of T. whipplei carriage in stool samples for 19 asymptomatic carriers is summarized on table 2. No correlation was observed between the length of the carriage and the profile observed obtained by Western blot.
DISCUSSION
Western blot serology tends to be subjective. We developed a process of automatic reading on the basis of our preliminary data. This study confirms the accuracy of this new T. whipplei serologic test on a large scale. Reproducibility and consistency of the assay have been assessed. Most of the subjects, including patients and asymptomatic carriers, presented the same profile for serum samples obtained at different times, and the blind test confirmed the previously obtained data. We can exclude the possibility that the different serological reactions do not reflect genotypic diversity of T. whipplei strains, because it has been shown that this diversity was not related to bacterial pathogenicity, and in this study, some patients with classic Whipple disease were infected by the same genotype [21] that was retrieved from the stools of asymptomatic carriers (data not shown). Therefore, this T. whipplei western blot serologic test, which is based on the analysis of GpTw110 before and after deglycosylation, is an effective tool for determining the differ-ence between patients with classic Whipple disease and T. whipplei carriers.
Accumulating evidence suggests that T. whipplei is a common microorganism in the environment [6, 7, 22] . Depending on the study, as many as 26% of sewer workers are asymptomatic carriers [7] . However, the prevalence of classic Whipple disease is relatively low and is estimated to be 1 case per 1,000,000 persons. Thus, the frequency of T. whipplei carriage detected in stool specimens has resulted in difficulties interpreting positive stool samples, as determined by polymerase chain reaction (PCR). Additionally, evidence of seroconversion after primary infection has been demonstrated recently in children with diarrhea (authors' unpublished data).
On the basis of this T. whipplei Western blot serologic test, patients with classic Whipple disease can be divided into 2 populations: individuals with no antibodies against T. whipplei, and individuals who exhibit a difference in reaction to glycosylated and deglycosylated proteins. The presence of IgM and/ or IgA is rare but is exclusively observed in patients with classic Whipple disease, as demonstrated elsewhere [1, 13] . IgGs are the most frequently detected, and IgG detection is parallel to the total immunoglobulin detection. Overall, total immunoglobulin detection against the antigenic membrane proteins accurately discriminated between patients with classic Whipple disease and T. whipplei carriers.
Recently, we proposed a strategy to diagnose classic Whipple disease that which was based on screening saliva and stool specimens with use of specific quantitative real-time PCR [18] . Indeed, presumptive diagnosis of classic Whipple disease should be highly suspected in patients with both saliva and stool specimens positive for T. whipplei, as determined by quantitative PCR, with a positive predictive value of 95.2%. In this other study [18] , the first screening was followed by quantitative PCR for T. whipplei in blood samples. However, the sensitivity of PCR on blood samples was low (16 [45.7%] of 35) for classic Whipple disease [18] . Therefore, T. whipplei Western blot serology should be performed to complement positive quantitative PCR results in stools and/or saliva specimens for the diagnosis of classic Whipple disease. Furthermore, a systematic screening of patients for classic Whipple disease could not be performed with this approach. Indeed, the lack of previous contact with the bacterium will affect the interpretation of the data. This methodology is not a diagnostic tool for patients with negative PCR results but should be reserved for patients with positive PCR results of saliva and/or stool samples.
Finally, these results also indicate the significance of different immune responses between patients with classic Whipple disease and asymptomatic carriers. The immune reactivity is low in patients with classic Whipple disease, whereas asymptomatic carriers develop an efficient response to T. whipplei. Reactivity is still low even when patients with Whipple disease receive adequate antibiotic therapy. This paradoxical response may be the consequence of an immune macrophage defect and inefficient organism clearance in patients. Recently, the importance of glycosylation of T. whipplei proteins in the pathogenesis of Whipple disease has been demonstrated [14] . This study confirmed on a large scale that the antibodies of patients with Whipple disease predominately recognize the glycoconjugated, but not the native form, of the protein, in contrast with asymptomatic carriers. Thus, T. whipplei glycosylation may impair the antibody-mediated immune recognition in patients and serve as a protective mechanism for T. whipplei from macrophage bactericidal activity. Such an intracellular masking system has not been previously described in bacteria, to our knowledge.
Our study clearly demonstrated that the classic humoral immune response of T. whipplei carriers was significantly higher than those of patients with classic Whipple disease. Paradoxically, the lack of and/or low immune response observed with use of T. whipplei Western blot assay is the current tool to differentiate patients with classic Whipple disease from T. whipplei carriers. Future studies on the prevalence of antibody response in the general population will be very interesting.
